

## LIST OF TABLES

<b>Table no.</b>	<b>Title</b>
Table 4.1	Validation parameters of HPLC analytical method
Table 4.2	Effect of $\beta$ -CD: cross linker ratio on the Particle Size, PI and ZP of different batches of nanosponges
Table 4.3	Saturation solubility studies of formulations with their enhancement factors
Table 4.4	Particle size analysis and EE of different batches of Drug loaded nanosponges
Table 4.5	Validation parameters for HPLC bioanalytical method
Table 4.6	Pharmacokinetic parameters for praziquantel in rats after oral administration of PZQ-NS and PZQ suspension(0.5% w/v Methyl Cellulose suspension of pure drug )at an equivalent praziquantel dose of 50 mg/kg (values are reported as mean $\pm$ s.d., n=6)
Table 5.1	Optimization of process variables
Table 5.2	Optimization of formulation Variables
Table 5.3	Effect of homogenization time (HT) on Particle size (PS), Polydispersity index (PI), and zeta potential (ZP)
Table 5.4	Effect of sonication time (ST) on Particle size (PS), Polydispersity index (PI), and zeta potential (ZP)
Table 5.5	Effect of volume of formulation (VF) on Particle size (PS), Polydispersity index (PI), and zeta potential (ZP)
Table 5.6	The effect of Lipophilic surfactant concentration (LSC) on characterizing parameters of SLN

Table 5.7	The effect of Hydrophilic surfactant concentration (LSC) on characterizing parameters of SLN
Table 5.8	The effect of Lipid concentration (LC) on characterizing parameters of SLN
Table 5.9	The effect of drug concentration (DC) on characterizing parameters of SLN
Table 5.10	The effect of Lipid types on characterizing parameters of SLN
Table 5.11	The effect of surfactant types on characterizing parameters of SLN
Table 5.12	The characterization parameters of optimized formulation for TM, TP and TS as lipid matrix
Table 5.13	Effect of storage at refrigerated conditions ( $5\pm 3^{\circ}\text{C}$ ) and at $25^{\circ}\text{C}/65\%$ RH on characterizing parameters of SLN
Table 5.14	Stability studies of various PZQ loaded SLN at different pH conditions
Table 5.15	Effect of sterilisation on characterizing parameters of PZQ SLN
Table 5.16	The <i>in-vitro</i> release kinetics model of optimized PZQ solid lipid nanoparticles in Phosphate buffer (pH 6.8) as dialysis medium.
Table 6.1	Optimization of binary lipid composition for PZQ-BSLN
Table 6.2	Effect of binary lipid composition on characterizing parameters of BSLN
Table 6.3	Optimization of drug concentration for PZQ-BSLN
Table 6.4	The effect of drug concentration (DC) on characterizing parameters of BSLN

Table 6.5	Effect of storage at refrigerated conditions (5±3°C) and at 25 °C/65% RH on characterizing parameters of BSLN
Table 6.6	Stability studies of various PZQ-BSLN at different pH conditions
Table 6.7	Effect of sterilisation on characterizing parameters of PZQ-BSLN
Table 6.8	The <i>in-vitro</i> release kinetics model of PZQ-BSLN in Phosphate buffer (pH 6.8) as dialysis medium.
Table 7.1	Animal group distribution for <i>in vivo</i> pharmacokinetic studies
Table 7.2	Pharmacokinetic parameters for praziquantel in rats after oral administration of PZQ-SLN, PZQ-BSLN and PZQ suspension at an equivalent praziquantel dose of 50 mg/kg
Table 7.3	Pharmacokinetic parameters for praziquantel in rats after single subcutaneous administration of PZQ-SLN, PZQ-BSLN and PZQ suspension at an equivalent praziquantel dose of 50 mg/kg
Table 7.4	Pharmacokinetic parameters for praziquantel in rats after single intramuscular administration of PZQ-SLN, PZQ-BSLN and PZQ suspension at an equivalent praziquantel dose of 50 mg/kg
Table 7.5	Pharmacokinetic parameters for praziquantel in rats after intra-duodenal administration of PZQ-SLNs at an equivalent praziquantel dose of 50 mg/kg to rats treated with Cycloheximide (CHM) and saline, respectively
Table 8.1	Anticestodal activity of PZQ SLN and PZQ-BSLN against larval and immature <i>H.diminuta</i> infections in rats
Table 8.2	Anticestodal activity of PZQ SLN and PZQ-BSLN against mature <i>H. diminuta</i> infections in rats